Old Web
English
Sign In
Acemap
>
Paper
>
MA 10.02 Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+
MA 10.02 Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+
2017
Ramaswamy Govindan
M. Cobo Dols
Santiago Ponce-Aix
Pieter E. Postmus
Conrad R. Lewanski
Jaafar Bennouna
J. Fischer
Oscar Juan Vidal
David J. Stewart
A. Ardizoni
J. Weaver
M. Wolfsteiner
M. Reck
Denis C. Talbot
Daniel Morgensztern
T.J. Ong
Keywords:
Oncology
Nab-paclitaxel
General surgery
Third line treatment
Durvalumab
Internal medicine
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]